Mapping Market Access Routes: Germination to Export Workflow Comparisons

Market access path mapping is the process of identifying, sequencing, and validating every step required to bring a product from concept to first commercial sale in a target market. For teams in regulated industries—medical devices, agrochemicals, specialty ingredients—the path is rarely a straight line. Regulatory submissions, clinical evidence, pricing approvals, and logistics each impose their own timelines and dependencies. This guide compares three common workflow models used to map those routes, helping you decide which approach fits your product, team, and target market.

Why Workflow Comparisons Matter for Market Access

Market access is often described as a funnel: start with many potential routes, narrow down through feasibility, then execute. But the shape of that funnel—how decisions are sequenced, how information flows, and where delays accumulate—varies dramatically between organizations. Teams that treat all market access projects with the same workflow often find themselves surprised by late-stage failures or budget overruns.

Consider a typical scenario: a diagnostic device company wants to launch in the EU and Southeast Asia simultaneously. The EU requires CE marking under IVDR, which demands clinical evidence and a notified body review. Southeast Asian markets often accept CE marking but add local registration steps. A linear workflow—finish EU, then start Asia—could add 12–18 months. A parallel workflow might run both tracks concurrently, but that multiplies regulatory risk if the EU pathway hits a snag. The choice of workflow model directly affects cost, speed, and probability of success.

We see three dominant workflow models in practice: sequential gate, parallel track, and adaptive loop. Each has a distinct logic and fits different product types, team sizes, and regulatory environments. By comparing them head-to-head, you can map your own project's constraints to the model that minimizes risk while hitting commercial timelines.

This article is intended as a general guide. For specific regulatory or legal decisions, consult a qualified professional.

Who Should Care About Workflow Models

Product managers, regulatory affairs leads, and market access strategists who plan multi-region launches. Also relevant for startup founders who need to prioritize limited resources across multiple market opportunities.

Core Idea: Three Workflow Models in Plain Language

At the highest level, a market access workflow defines the order in which tasks are completed and how decisions propagate. The three models we compare are:

• Sequential Gate: Complete one phase entirely before moving to the next. Each phase ends with a go/no-go decision. Classic stage-gate model.
• Parallel Track: Run multiple work streams simultaneously, with coordination points where outputs are integrated. Common in large pharma for global filings.
• Adaptive Loop: Work in short cycles, re-assessing the route after each cycle based on new information. Borrowed from agile software development, adapted for regulatory pathways.

Each model handles uncertainty differently. Sequential gate reduces risk by ensuring each phase is validated before committing resources to the next—but it's slow. Parallel track accelerates timelines by overlapping activities, but it increases coordination complexity and the cost of rework if one track fails. Adaptive loop offers flexibility when the pathway is poorly understood, but it can be difficult to manage in highly regulated environments where documentation and approvals are linear by nature.

Let's unpack the mechanics of each model before comparing them directly.

Sequential Gate: Predictable but Slow

This model works well when the pathway is well-understood and regulatory requirements are stable. Each gate—feasibility, preclinical, clinical, regulatory submission, pricing, launch—has clear criteria. The team knows exactly what evidence is needed at each step. The downside: if a gate fails, all previous work may need revisiting, and the timeline stretches linearly.

Parallel Track: Fast but Complex

Parallel track splits the market access process into independent streams that run concurrently. For example, one team prepares the regulatory dossier while another runs the pricing study and a third begins logistics setup. Regular sync points ensure alignment. This model can cut total time by 30–50% compared to sequential, but it requires strong project management and a buffer for rework.

Adaptive Loop: Flexible but Unpredictable

Adaptive loop treats market access as a series of short experiments. Each cycle includes planning, execution, review, and adjustment. This model is useful for novel products where the regulatory pathway is unclear—for example, a first-in-class gene therapy where regulators themselves are learning. The trade-off is that timelines are hard to forecast, and some stakeholders (investors, senior management) may prefer a more predictable plan.

How the Models Work Under the Hood

To understand why each model behaves differently, we need to look at three underlying mechanisms: dependency management, information flow, and decision points.

Dependency Management

In a sequential gate model, dependencies are hard: Task B cannot start until Task A is complete. This is simple to manage but creates long critical paths. Parallel track uses soft dependencies—Task B can start with preliminary data from Task A, but must integrate the final version later. Adaptive loop minimizes dependencies by breaking work into small, self-contained cycles that can be reordered as needed.

For example, in a medical device launch, clinical data is a prerequisite for regulatory submission. In a sequential model, the team waits for the full clinical report. In a parallel model, they might start drafting the regulatory dossier based on an interim analysis, then update it. In an adaptive loop, they might run a small pilot study first, then decide whether to proceed to a full trial or adjust the indication.

Information Flow

Information flow affects how quickly the team learns about problems. Sequential gate provides clear feedback at each gate—but only after the entire phase is done. Parallel track can surface issues earlier because multiple teams are working simultaneously and sharing updates. Adaptive loop provides the fastest feedback, as each cycle ends with a review, but the frequency of reviews can be exhausting.

A common failure in parallel track is information silos: the pricing team negotiates a price that the regulatory team later finds unsupportable because the clinical evidence doesn't justify it. Regular cross-functional syncs are essential.

Decision Points

Every model has decision points where the team decides to continue, pivot, or stop. Sequential gate has the fewest decision points (one per gate), but each decision is high-stakes. Parallel track adds more decision points (at each sync), which can slow things down if not managed efficiently. Adaptive loop has the most decision points (each cycle end), which can lead to analysis paralysis if the team lacks clear criteria.

We recommend mapping your product's dependency graph before choosing a model. If dependencies are tight and sequential, a gate model may be the only safe option. If you can decouple work streams, parallel track becomes attractive. If the pathway is highly uncertain, adaptive loop may save you from large sunk costs.

Worked Example: Launching a Diagnostic Test in Three Regions

Let's walk through a composite scenario to see how each model plays out. A mid-size diagnostics company plans to launch a new test for a rare disease in the EU, the US, and Brazil. The test is based on a novel biomarker; regulatory pathways are defined but the clinical evidence package is still being built.

Sequential Gate Approach

The team decides to complete the EU pathway first. They run the clinical study, submit the CE marking application, and wait for notified body review. Only after EU approval do they begin the US FDA 510(k) submission, using the EU clinical data. Then they start Brazil's ANVISA registration. Total timeline: 36 months. Risk: low, because each step uses validated data from the previous step. But the company misses early revenue in the US and Brazil, and a competitor may enter first.

Parallel Track Approach

The team runs the clinical study once but prepares regulatory dossiers for all three regions simultaneously. They submit to the EU notified body and FDA at the same time, using the same clinical data. Brazil's registration begins after EU submission, since ANVISA often requires EU approval. Total timeline: 24 months. Risk: moderate—if the EU notified body requests additional data, both the EU and US submissions may need updates, causing rework in both tracks.

Adaptive Loop Approach

The team starts with a small feasibility study to confirm the biomarker's performance. Based on results, they design a full clinical study but also explore a potential alternative indication. They submit a preliminary dossier to the EU for scientific advice, then adjust the study protocol. After the full study, they submit to the EU and US, but pause Brazil until EU feedback arrives. Total timeline: 30 months (but with possibility of earlier launch if the alternative indication proves faster). Risk: higher, but the team can pivot if initial results are disappointing.

This example shows that the choice of model depends on the team's risk tolerance, competitive pressure, and regulatory familiarity. There is no universally correct model.

Edge Cases and Exceptions

No workflow model works for every product or market. Here are common edge cases where the standard models need modification.

Combination Products

When a product combines a drug, device, and/or biologic, regulatory pathways often overlap in unpredictable ways. Sequential gate may be too slow, while parallel track risks submitting inconsistent dossiers to different agencies. A hybrid model—parallel for independent work streams, sequential for interdependent ones—often works best. For example, the device component and drug component might be developed in parallel, but the combination submission must be sequential after both are ready.

Markets with Unclear Requirements

Some emerging markets have evolving regulatory frameworks. In such cases, adaptive loop is valuable: submit a preliminary inquiry, receive feedback, adjust, then proceed. Sequential gate would waste time waiting for requirements that may change. Parallel track is risky because the team may invest in a submission that the regulator later rejects on new grounds.

Very Small Teams

A startup with two regulatory staff cannot realistically run parallel tracks across three regions. Sequential gate may be the only feasible model, even if it's slower. However, they can use an adaptive loop mindset within each gate: break the gate into small cycles to learn quickly and adjust.

Products with Short Lifespans

For seasonal products or those with rapid technology cycles (e.g., diagnostic kits for emerging pathogens), speed is everything. Parallel track is the default, even with higher risk. Adaptive loop may be too slow due to frequent reviews. Sequential gate is rarely appropriate.

Regulatory Harmonization Zones

In regions with mutual recognition (e.g., EU member states, or ASEAN countries with some harmonization), parallel track can be simplified. You may submit to one reference country and then use that approval to fast-track others. This is a special case of parallel track with reduced complexity.

Limits of Workflow Comparisons

While workflow models are useful for planning, they have inherent limitations that teams should recognize.

Models Are Simplifications

Real market access paths are messier than any model. Unexpected regulatory changes, competitor actions, or supply chain disruptions can force a replan. A model that looks good on paper may fail in practice because it doesn't account for human factors—like a key reviewer leaving the agency, or a team member's burnout from parallel track pressure.

No Model Eliminates Regulatory Risk

Even the most carefully chosen workflow cannot guarantee approval. Regulatory agencies have their own timelines and may request additional data regardless of your model. The model affects how quickly you can respond, but not whether you will succeed. Teams sometimes over-rely on the model as a risk mitigation tool, neglecting the actual evidence generation and submission quality.

Cost of Switching Models Mid-Project

Once a team commits to a workflow, changing models mid-project is expensive. Documentation, team roles, and timelines are built around the original model. Switching from sequential to parallel, for example, may require reallocating resources and renegotiating contracts with CROs. It's better to choose the right model early, or use a hybrid that can flex without a full restart.

Comparison Tables Are Static

The comparison tables we provide (and you may create) are snapshots. Market access environments evolve. A model that works today may be suboptimal next year as regulations change. Revisit your workflow choice periodically, especially when entering a new market or launching a new product line.

Practical Next Steps

After reading this comparison, we suggest three actions: (1) Map your current project's dependencies and uncertainty level using a simple matrix (low/medium/high for each). (2) Select a primary workflow model and identify one or two contingency adjustments for likely edge cases. (3) Schedule a cross-functional review of the chosen model with regulatory, clinical, commercial, and supply chain teams to surface hidden dependencies. These steps will help you move from abstract comparison to concrete planning.